OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
Business Wire•06/10/2026•08:00 ET
0
Key Highlights
- ➤19 partner clinical trials could reach primary completion in late 2026 and 2027
- ➤xPloration launches to all customers this month, targeting a $500M-plus market
- ➤xPloration revenue expected at $2M-$3M in 2026
- ➤xPloration revenue expected to double in 2027 and again in 2028
- ➤OmniAb introduces OmniTides peptide discovery platform powered by OmniUltra
Expert Statements
Matt Foehr, Chief Executive Officer of OmniAb
“We look forward to bringing together our investment community and sharing a closer look at our technologies and capabilities, our strategy and the exciting opportunities ahead”
Matt Foehr, Chief Executive Officer of OmniAb
“At our Investor & Analyst Day, we have the opportunity to discuss our priorities and our plans related to our increasingly efficient business model, review the variety of ways we are creating value with technology licensing, and outline how we are positioning the company for sustainable, long-term growth.”
Matt Foehr, Chief Executive Officer of OmniAb
“Those attending here at our Emeryville headquarters are also getting to experience demonstrations of our powerful xPloration platform, that we see as an additional pillar of significant value and growth for the business.”
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
Formal presentation begins today, October 6, 2026, at 11 a.m. ET
Get started
Create a free account to read the full story.